[A21-108] Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2021
Commission awarded on 30.08.2021 by the Federal Joint Committee (G-BA).
Adjuvant treatment of carcinoma of the oesophagus or the gastroesophageal junction in adults with pathological residual disease after prior neoadjuvant chemoradiotherapy.
Indication of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.